Dapoxetine Impurity 26 HCl, identified by its CAS number 2414049-30-0, is a chemical compound that serves as an impurity associated with the pharmaceutical agent dapoxetine, which is primarily used for the treatment of premature ejaculation. As an impurity, it may arise during the synthesis or degradation of dapoxetine and is typically characterized by its hydrochloride salt form. The compound's structural characteristics, including its molecular formula and functional groups, can influence its solubility, stability, and reactivity. Impurities like Dapoxetine Impurity 26 HCl are critical to assess during drug development and quality control, as they can affect the efficacy and safety of the final pharmaceutical product. Regulatory agencies often require detailed characterization and quantification of such impurities to ensure compliance with safety standards. Understanding the properties of this impurity, including its potential biological activity and toxicological profile, is essential for pharmaceutical manufacturers to mitigate risks associated with drug formulation.

DapoxetineImpurity26HCl

2414049-30-0: Dapoxetine Impurity 26 HCl, identified by its CAS number 2414049-30-0, is a chemical compound that serves as an impurity associated with the pharmaceutical agent dapoxetine, which is primarily used for the treatment of premature ejaculation. As an impurity, it may arise during the synthesis or degradation of dapoxetine and is typically characterized by its hydrochloride salt form. The compound's structural characteristics, including its molecular formula and functional groups, can influence its solubility, stability, and reactivity. Impurities like Dapoxetine Impurity 26 HCl are critical to assess during drug development and quality control, as they can affect the efficacy and safety of the final pharmaceutical product. Regulatory agencies often require detailed characterization and quantification of such impurities to ensure compliance with safety standards. Understanding the properties of this impurity, including its potential biological activity and toxicological profile, is essential for pharmaceutical manufacturers to mitigate risks associated with drug formulation.

CAS 2414049-30-0

DapoxetineImpurity26HCl

Dapoxetine Impurity 26 HCl

Ref: 4Z-D-2038